Aurobindo derives over 70% of its revenues from international operations, primarily from the U.S. The company plans to expand its product portfolio with high-value products in oncology, hormones, biosimilars, and novel drug delivery solutions, while projecting EBITDA margins of 20-21% and over €1 billion revenue from Europe for FY'26.
Cyborg Score Rationale
Revenue in 2024 was ₹317.24 billion, an increase of 9.39% compared to the previous year, and Q3 FY26 consolidated revenue rose 8.4% year-on-year to ₹8,646 crores. The company generated a net cash inflow of USD 118 million, improving its net cash position, demonstrating solid operational execution despite regulatory headwinds.
Top Insights
The Pen-G initiative supported by government policy and significant Lannett acquisition present unique growth vectors, with diversified geographical presence positioning Aurobindo for continued expansion
Pen-G facility ramp-up is progressing well, with anticipated annual production exceeding 10,000 metric tonnes
Company aims to achieve EBITDA breakeven for its China plant by Q3 or Q4 of FY'26, underscoring its commitment to optimizing international operations
Most recent deal was acquisition of Khandelwal Laboratories non-oncology prescription formulations business on January 1, 2026
Named Competitors
Generics Business — Strong U.S. generics and specialty products
Generics & Specialty Products — U.S.-driven generics with specialty focus
Generic Pharmaceuticals — Indian pharma with global generics presence
Generic Pharmaceuticals — Diversified Indian pharma company
Recent Developments
(February 2026) Q3 FY26 earnings showing 8.4% YoY revenue growth to ₹8,646 crores with strong gross margins of 59.7%
(January 2026) Acquisition of Khandelwal Laboratories non-oncology prescription formulations business
(December 2025) Strong Q3 performance with net cash generation of USD 118 million and optimized net cash position
(November 2025) Announced FY'26 targets including €1 billion Europe revenue and 20-21% EBITDA margins
Open the full interactive Aurobindo Pharma Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.